Infliximab regulatory update

Australia approved Inflectra infliximab, a biosimilar of autoimmune drug Remicade infliximab from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) and Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.). The biosimilar of the humanized mAb against tumor necrosis factor (TNF) alpha is approved to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), adult and pediatric Crohn’s disease (CD), refractory fistulizing CD, adult and pediatric ulcerative colitis (UC) and plaque psoriasis. ...